Peptide Drug Delivery Systems

Peptides present a fundamental delivery problem. They are large enough that passive diffusion across biological membranes is negligible. They are hydrophilic, making lipid bilayer crossing difficult. They are substrates for proteases throughout the body — in the stomach, intestinal lumen, blood, and at tissue surfaces. And most peptides over 10 amino acids are too large for oral absorption through paracellular pathways. These properties explain why the overwhelming majority of approved peptide drugs require injection. Overcoming these barriers is the central challenge of peptide formulation science.

Subcutaneous injection

Subcutaneous (SC) injection remains the gold standard for peptide delivery because it bypasses the gastrointestinal tract entirely. The peptide is deposited in the adipose tissue layer beneath the skin, where it enters the systemic circulation through capillary and lymphatic absorption. Bioavailability is typically 60-80% for SC peptide injections — far higher than any non-invasive route currently achieves.

Modern autoinjector pens (similar to insulin pens) have significantly improved patient experience. Pre-filled, single-dose devices with fine-gauge needles (29-31G) reduce injection pain and complexity. The once-weekly dosing schedules of semaglutide and tirzepatide have further reduced injection burden. Nevertheless, needle aversion remains a significant barrier to treatment initiation and adherence, driving investment in alternative delivery routes.

Oral delivery

The oral route is the most desired but most difficult for peptides. The gastrointestinal tract presents a multi-layered barrier: acidic gastric pH (1.5-3.5) denatures many peptides, pepsin and pancreatic proteases (trypsin, chymotrypsin, elastase) degrade them, and the intestinal epithelium blocks absorption of molecules above approximately 500-700 Da. Oral bioavailability for unformulated peptides is typically below 1-2%.

SNAC technology. Sodium N-[8-(2-hydroxybenzoyl)amino]caprylate (SNAC) is the absorption enhancer used in oral semaglutide (Rybelsus). SNAC creates a localized alkaline microenvironment in the stomach that protects semaglutide from acid degradation, promotes monomeric peptide conformation, and transiently enhances transcellular absorption across the gastric epithelium. Even with this technology, oral bioavailability is only approximately 0.4-1% — requiring a 14 mg oral dose to achieve plasma levels comparable to 0.5 mg injected. The tablet must be taken on an empty stomach with no more than 4 oz of water, and the patient must wait at least 30 minutes before eating. These constraints reflect how narrow the absorption window is.

Orforglipron. A fundamentally different approach — orforglipron is a non-peptide, small-molecule GLP-1 receptor agonist. By mimicking the peptide's receptor binding with a molecule small enough for conventional oral absorption, it sidesteps the peptide delivery problem entirely. Oral bioavailability is substantially higher than SNAC-formulated semaglutide, with no food-timing restrictions. Phase 3 trials have shown clinically meaningful weight loss and glycemic control.

BPC-157. Body Protection Compound-157 is notable as an apparently acid-stable peptide. Unlike most peptides, BPC-157 appears to retain activity after oral administration in animal studies, suggesting inherent resistance to gastric degradation. The mechanism of this stability is not fully characterized, though the peptide's compact structure and resistance to acid hydrolysis likely contribute. Oral BPC-157 has not been validated in controlled human clinical trials.

Nasal delivery

The nasal mucosa offers several advantages for peptide delivery: large surface area (approximately 160 cm2), thin epithelium with rich vascularity, avoidance of hepatic first-pass metabolism, and potential for direct nose-to-brain transport via the olfactory and trigeminal nerve pathways.

Semax (a synthetic ACTH(4-10) analog) and Selank (a tuftsin analog) are both administered intranasally and have been approved in Russia for cognitive and anxiolytic indications, respectively. The nasal route is particularly logical for neuroactive peptides, as some fraction of the administered dose may reach the CNS directly through the olfactory epithelium, bypassing the blood-brain barrier. Nasal bioavailability for peptides typically ranges from 1-10% — higher than oral but still low compared to injection.

Limitations include mucociliary clearance (the nasal mucosa replaces its mucus layer every 15-20 minutes), variability due to nasal congestion or rhinitis, and a practical dose ceiling — the nasal cavity can only accommodate approximately 150-200 microliters per nostril.

Transdermal delivery

Transdermal delivery avoids first-pass metabolism and provides sustained release, but the stratum corneum (the outermost skin layer) is an effective barrier against hydrophilic molecules above approximately 500 Da — excluding virtually all therapeutic peptides.

Microneedle arrays circumvent this barrier mechanically. Arrays of micron-scale needles (typically 200-800 micrometers in length) penetrate the stratum corneum without reaching dermal nerve endings, creating painless microchannels for peptide absorption. Dissolving microneedle patches — where the peptide is incorporated into the needle material itself, which dissolves after insertion — are in clinical development for insulin and other peptide hormones.

Iontophoresis uses a low electrical current to drive charged peptide molecules across the skin. It is approved for delivery of small molecules (lidocaine, fentanyl) and has been investigated for peptides, but depth of penetration and achievable plasma levels remain limiting factors for larger peptides.

Nanoparticle encapsulation

Nanoparticle systems protect peptides from enzymatic degradation, enhance cellular uptake, and can provide controlled release.

Liposomes — phospholipid bilayer vesicles (50-200 nm diameter) that encapsulate hydrophilic peptides in their aqueous core. Liposomes are biocompatible and well-established in drug delivery, though stability in the GI tract and rapid clearance by the reticuloendothelial system remain challenges.

PLGA nanoparticles — poly(lactic-co-glycolic acid) is an FDA-approved biodegradable polymer. PLGA nanoparticles encapsulate peptides and release them as the polymer matrix degrades over days to weeks, enabling depot formulations from a single injection. Leuprolide depot (Lupron Depot) uses this approach for sustained GnRH agonist delivery over 1-6 months.

PEGylated systems — coating nanoparticles with polyethylene glycol (PEG) creates a hydrophilic "stealth" layer that reduces opsonization and extends circulation time.

Lipidation and albumin binding

Rather than encapsulating the peptide, lipidation modifies the peptide itself. Attaching a fatty acid chain enables reversible, non-covalent binding to serum albumin, which has a circulating half-life of approximately 19 days. The albumin-bound peptide forms a slowly dissociating reservoir in the bloodstream.

Semaglutide uses a C18 octadecandioic fatty diacid attached via a linker to Lys26, achieving a half-life of approximately 7 days (versus 2 minutes for native GLP-1). Tirzepatide uses a C20 eicosandioic fatty diacid, also yielding once-weekly pharmacokinetics. Liraglutide uses a simpler C16 palmitic acid attachment with a shorter half-life of approximately 13 hours (once-daily dosing). The progression from C16 to C18 to C20 acylation illustrates how incremental modifications to the lipid moiety can substantially alter pharmacokinetics without changing the peptide's receptor pharmacology.

These lipidation strategies have transformed the GLP-1 agonist class from continuous-infusion research tools into practical medicines, and the same principles are now being applied to other peptide drug candidates across therapeutic areas.